Back

Myeloperoxidase inhibitor AZD4831 target engagement and safety in a phase 2a study in patients with heart failure with preserved ejection fraction (SATELLITE)

1 July 2021 (14:00 - 15:00)
Organised by:
Congress Presentation Part of: Chronic Heart Failure - Treatment 2 Pharmacotherapy HFA Premium Access Heart Failure 2021

About the speaker

Photo
Professor Carolyn S P Lam

Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)

7 More presentations in this session

Presentation thumbnail
Catheter-based cardiopulmonary nerve stimulation impacts left ventricular contractility and relaxation: first in human experience
Doctor S. Mickelsen (Cardiff by the Sea, US)
Abstract Slides Video
Presentation thumbnail
Impact of COVID-19 lockdown measures on heart transplant recipients
Doctor A. Maestro-Benedicto (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Incremental efficacy of medical therapy for chronic heart failure with a reduced ejection fraction: a systematic review and network meta-analysis
Doctor V. De Marzo (Genoa, IT)
Abstract Slides Video
Presentation thumbnail
Myeloperoxidase inhibition reverses the inflammatory proteomic pattern in heart failure with preserved ejection fraction
Doctor E. Michaelsson (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Effect of sodium restriction in stable patients with heart failure; randomized controlled trial
Doctor J. Ivey Miranda (Mexico City, MX)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic Heart Failure - Treatment 2

The Event

Event poster

Heart Failure 2021

1 July 2021 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Myeloperoxidase as a prognostic marker for adverse events in patients with chronic heart failure in 12 month follow-up
20 May 2023
thumbnail
Congress Presentation
Safety, pharmacokinetics, and pharmacodynamics of AZD3427, a functionally selective long acting relaxin mimetic agonist of the RXFP1 receptor
20 May 2023
thumbnail
Congress Presentation
Effect of 5-lipoxygenase-activating protein inhibiton on coronary atherosclerosis progression in patients with recent acute coronary syndrome: the PASSIVATE randomised clinical trial
1 September 2025
thumbnail
Congress Presentation
HDAC6 inhibition improves diastolic function in a mouse model of heart failure with preserved ejection fraction
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources